U.S. market Open. Closes in 5 hours 7 minutes

LGND | Ligand Pharmaceuticals Incorporated Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 103.00 - 105.47
52 Week Range 67.72 - 129.90
Beta 1.09
Implied Volatility 51.23%
IV Rank 80.48%
Day's Volume 134,849
Average Volume 107,149
Shares Outstanding 19,255,400
Market Cap 2,024,512,756
Sector Healthcare
Industry Biotechnology
IPO Date 1992-11-18
Valuation
Profitability
Growth
Health
P/E Ratio -477.91
Forward P/E Ratio 78.17
EPS -0.22
1YR Price Target 180.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 58
Country USA
Website LGND
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
*Chart delayed
Analyzing fundamentals for LGND we got that it has average fundamentals where Valuation is considered to be slightly undervalued, Profitability is poor, Growth is exceptionally good and Health is very strong. For more detailed analysis please see LGND Fundamentals page.

Watching at LGND technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on LGND Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙